Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/jcm10091841
Keywords
autologous stem cell transplantation; clinical study; combination chemotherapy; high dose melphalan therapy; in vitro and in vivo studies; multiple myeloma
Categories
Funding
- Polish National Centre for Research and Development [POWR.03.02.00-00-I033/16-00]
Ask authors/readers for more resources
This review discusses the pharmacokinetics and pharmacodynamics of melphalan therapy in multiple myeloma, as well as its use in innovative treatments such as drug carriers to reduce toxicity, combination therapy to enhance efficacy, and chemical modification to improve antitumor activity.
Multiple myeloma (MM) accounts for 10% of all hematological malignancies, and it is the second most common hematological neoplasm for which chemotherapy is an important pharmacological treatment. High dose melphalan followed by autologous stem cell transplantation remains the standard of treatment for transplant-eligible patients with MM. In this review, we describe aspects of the pharmacokinetics and pharmacodynamics of melphalan therapy and related compounds. In addition, we describe the use of melphalan in innovative therapies for the treatment of MM, including the development of drug carriers to reduce systemic toxicity, combination therapy to improve the effectiveness of cancer therapy, and the chemical modification of the melphalan molecule to improve antitumor activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available